CTOs on the Move


 
physIQ is the leader in digital medicine, dedicated to generating unprecedented health insight using continuous wearable biosensor data and advanced analytics. Its industry-leading, enterprise-ready cloud platform continuously collects and processes data from wearable biosensor using a deep portfolio of FDA-cleared analytics. The company has published one of the most rigorous clinical studies to date in digital medicine and are pioneers in developing, validating, and achieving regulatory approval of Artificial Intelligence-based analytics. With applications in both clinical trial support and healthcare, physIQ is transforming continuous physiological data into insight for health systems, payers, and pharmaceutical companies
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.physiq.com
  • 200 West Jackson Boulevard Suite 550
    Chicago, IL USA 60606
  • Phone: 800.516.7902

Executives

Name Title Contact Details

Similar Companies

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.

Synthonics

Synthonics is a Blacksburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agadia

Agadia is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tracon Pharmaceuticals

Tracon Pharmaceuticals, is a biopharmaceutical company that licenses, develops, and commercializes targeted therapies for cancer and age-related macular degeneration. The current pipeline takes advantage of established platform technologies to block novel pathways implicated in cancer growth and angiogenesis.

Runatek

At Runatek, were ending the Opioid Crisis with innovative technology